The bill imposes a number of controls, such as minimum discounts off of non-federal AMP, as well as a framework for how to define “fair” prices and how the negotiating process will determine prices based on factors such as R&D costs, unmet need, therapeutic gain, and comparative effectiveness.
What “Negotiating” With Medicare Means For Drug Makers: A Mixture Of Price Controls And Actual Negotiations
